Illumina’s Staff Product Manager of Infectious Disease Michael Oberholzer, Ph.D., and Chief Medical Officer Phil Febbo, M.D., offer their perspective on the novel Coronavirus SARS-CoV-2 (2019-nCoV) outbreak.
A five-country study found that eating a Mediterranean diet for a year boosts the types of gut bacteria linked to “healthy” aging while reducing those associated with harmful inflammation in the elderly.
The study could signal a potential treatment breakthrough for patients with this form of breast cancer, which disproportionately affects and tends to develop more aggressively in black women.
While the results showed a strong association between polygenic risk scores and CHD, with those scoring highest on this calculator at baseline most likely to experience cardiac events over the follow-up period, the results were roughly the same using the ACC/AHA calculator.
GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.
The investment allows Seqster to ramp up development of its technology which streamlines patient recruitment for clinical trials by matching consenting patients based on their EHR, genomic, and real-time digital data delivered by wearable monitoring devices.
The chaperone protein Clusterin shuttles misfolded proteins directly into cells for degradation, a finding that could point to new therapeutic targets for AD and other neurodegenerative diseases.
Although CTCs can be detected in melanoma patients, there is limited data regarding their significance in stage III (node-positive) disease. This prospective study was based on earlier studies that found CTCs in a significant number of breast cancer patients was associated with relapse, independent of other prognostic methods.
The researchers developed new computational tools and biological model systems to study the link between a strong cancer driver gene that impacts changes in proteins related to alternative splicing regulation.
If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...
Dubbed FUSIL (Full Spectrum of Intolerance to Loss-of-function), the open-source database created by EMBL-EBI is intended to help researchers identify rare disease mutations by categorizing which genes are essential for supporting life.
This look at endometrial cancer offers insights to better identify which patients will need aggressive treatment and which won't, clues on why certain treatments are not effective with some patients, and suggestions for drugs to target proteins CDK12, SMARCA4, and PML.
Cell phone users with single nucleotide polymorphisms (SNPs) in four of the genes studied were more than two times more likely to develop cancer. Overall, the researchers found 10 SNPs that appear to increase the risk of thyroid cancer among cell phone users.
As demand continues to grow for more data to inform precision medicine, digital biomarkers represent a new class of biomarkers that provide information in real time.
Women whose plasma contained circulating tumor DNA had only a 56% chance of being cancer-free two years following chemotherapy and surgery, while those without it had an 81% chance the cancer would not return in the same time span.
OncoDNA said the financing is designed to support rapid international growth, accelerate software development, and carry out hiring initiatives.
The findings suggest that tumor development can span the entire lifetime of an individual, so the mutations that initiate cancer progression may arise decades before diagnosis.
In this most recent ASC study, researchers mapped the genes of 35,584 individuals, of whom 11,986 had autism, to determine how many times each gene is affected by variants with protein disrupting consequences.
The maps detail the intricacies and complexity of the breast cancer landscape—comprising cancer cells, immune cells and connective tissue—and how it varies both between, and within, tumors depending on their unique genetic makeup.
While much progress has been made, it is fair to say more advances are needed before precision medicine and/or genomic medicine is standard practice. So how will we get there? Read on as four industry watchers share with you their thought on what may happen in the next ten years to advance the field.
When tested in cancer-bearing mice, a single dose of the bacteria continuously produced and released the anti-PD-L1 and anti-CTLA-4 nanobodies, triggering an immune response that led to tumor regression. The researchers say the platform could be used to deliver multiple immunotherapies simultaneously, enabling the release of effective therapeutic combinations for hard-to-treat cancers.
The Phase I clinical trial to evaluate CRISPR-Cas9-edited T cells in humans with advanced cancer, led by immunotherapy pioneer Carl June, has reported the patients experienced no negative side effects, and that the engineered T cells persisted in their bodies for months.
Lucid seeks to improve the diagnosis of Barrett’s Esophagus (BE), with and without dysplasia—a progression of precursor conditions that culminate in highly lethal esophageal cancer (EAC), as well as EAC itself, in patients with gastroesophageal reflux disease (GERD).
Polygenic risk scores deliver a more precise estimation of individualized risk of developing a disease, with heart disease and cancer leading the way.
Up-and-Coming Diagnostic Test Developers Emerge as Consolidation Thins the Field.